Flexible long-acting HIV medicines for children
Dose flexible ultra-long-acting prodrug formulations for pediatric populations
['FUNDING_OTHER'] · UNIVERSITY OF NEBRASKA MEDICAL CENTER · NIH-11261129
Injectable HIV medicines given every six months to help children and teens avoid daily pills.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEBRASKA MEDICAL CENTER (nih funded) |
| Locations | 1 site (OMAHA, UNITED STATES) |
| Trial ID | NIH-11261129 on ClinicalTrials.gov |
What this research studies
Researchers are creating injectable forms of common HIV drugs that slowly release medicine over months so children do not need daily oral pills. They have a six-month injectable form of bictegravir and plan to make matching long-acting versions of emtricitabine and tenofovir to form a complete regimen. The team uses nanoformulation and prodrug chemistry with child-friendly ingredients and dose-flexible options for different ages and weights. Studies will track how the drugs are absorbed, how long they stay at effective levels, and safety in pediatric-appropriate tests.
Who could benefit from this research
Good fit: Children and adolescents living with HIV-1 who need an alternative to daily oral antiretroviral therapy or who might benefit from long-acting injectable options.
Not a fit: People with viral resistance to integrase inhibitors, known allergies to study components, or infants outside the tested age/weight ranges may not benefit from these formulations.
Why it matters
Potential benefit: Could allow children living with HIV to receive treatment every six months instead of taking daily pills, potentially improving adherence and viral control.
How similar studies have performed: Long-acting injectable HIV drugs have shown success in adults, but creating safe, dose-flexible versions specifically for children is a newer and less-tested approach.
Where this research is happening
OMAHA, UNITED STATES
- UNIVERSITY OF NEBRASKA MEDICAL CENTER — OMAHA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EDAGWA, BENSON — UNIVERSITY OF NEBRASKA MEDICAL CENTER
- Study coordinator: EDAGWA, BENSON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome